[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T, Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer; 2002 Oct 15;95(8):1685-95
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
  • BACKGROUND: To the authors' knowledge, the significance of postoperative adjuvant chemotherapy in pancreaticobiliary carcinoma has not yet been clarified.
  • A randomized controlled study evaluated the effect of postoperative adjuvant therapy with mitomycin C (MMC) and 5-fluorouracil (5-FU) (MF arm) versus surgery alone (control arm) on survival and disease-free survival (DFS) for each specific disease comprising resected pancreaticobiliary carcinoma (pancreatic, gallbladder, bile duct, or ampulla of Vater carcinoma) separately.
  • METHODS: Between April 1986 and June 1992, a total of 508 patients with resected pancreatic (n = 173), bile duct (n = 139), gallbladder (n = 140), or ampulla of Vater (n = 56) carcinomas were allocated randomly to either the MF group or the control group.
  • ]) at the time of surgery and 5-FU (310 mg/m(2) i.v.) in 2 courses of treatment for 5 consecutive days during postoperative Weeks 1 and 3, followed by 5-FU (100 mg/m(2)orally) daily from postoperative Week 5 until disease recurrence.
  • RESULTS: After ineligible patients were excluded, 158 patients with pancreatic carcinoma (81 in the MF group and 77 in the control group), 118 patients with bile duct carcinoma (58 in the MF group and 60 in the control group), 112 patients with gallbladder carcinoma (69 in the MF group and 43 in the control group), and 48 patients with carcinoma of the ampulla of Vater (24 in the MF group and 24 in the control group) were evaluated.
  • Good compliance (> 80%) was achieved with MF treatment.
  • There were no apparent differences in 5-year survival and 5-year DFS rates between patients with pancreatic, bile duct, or ampulla of Vater carcinomas.
  • The most commonly reported adverse drug reactions were anorexia, nausea/emesis, stomatitis, and leukopenia, none of which were noted to be serious.
  • CONCLUSIONS: The results of the current study indicate that gallbladder carcinoma patients who undergo noncurative resections may derive some benefit from systemic chemotherapy.
  • However, alternative modalities must be developed for patients with carcinomas of the pancreas, bile duct, or ampulla of Vater.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / drug therapy. Gallbladder Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Mitomycins / administration & dosage. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • [CommentIn] Cancer Treat Rev. 2003 Apr;29(2):135-7 [12670458.001]
  • (PMID = 12365016.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitomycins; U3P01618RT / Fluorouracil; FuMi protocol
  •  go-up   go-down


2. Sata N, Tsukahara M, Koizumi M, Yoshizawa K, Kurihara K, Nagai H, Someya T, Saito K: Primary small-cell neuroendocrine carcinoma of the duodenum - a case report and review of literature. World J Surg Oncol; 2004;2:28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Small-cell neuroendocrine carcinoma in the duodenum is an extremely rare neoplasm with poor prognosis.
  • Duodenoscopy and hypotonic duodenography revealed a 3 x 3 cm protruding tumor with ulcerations situated opposite the ampulla of Vater in the second part of the duodenum.
  • Local excision of the tumor was performed, followed by adjuvant chemotherapy with 5-fluoro uracil and leucovorin.
  • Examination of the tumor by immunohistochemistry and electron microscopy indicated it to be neuroendocrine in nature, expressing synaptophysin and AE1/AE3, and containing dense core granules.
  • CONCLUSIONS: Most cases of small-cell neuroendocrine carcinoma in the duodenum show rapid progression of the disease, and even radical surgery with or without chemotherapy do not prevent death.
  • This subtype appears to have a much better prognosis, and may be amenable to local excision, if the lesion is away from the ampulla of Vater.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):703-13 [1696069.001]
  • [Cites] Hepatogastroenterology. 1990 Apr;37(2):247-52 [2160422.001]
  • [Cites] Arch Pathol Lab Med. 1986 Apr;110(4):317-20 [3006628.001]
  • [Cites] Cancer. 1968 Dec;22(6):1163-72 [5705778.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1645-61 [6089995.001]
  • [Cites] Am J Clin Pathol. 1983 Nov;80(5):755-61 [6314801.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):517-9 [7550864.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):593 [10805848.001]
  • [Cites] Dig Dis Sci. 2001 Oct;46(10):2162-5 [11680591.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1616-26 [12404236.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1502-4 [1325273.001]
  • [Cites] Am J Clin Pathol. 1992 Mar;97(3):411-5 [1371903.001]
  • [Cites] Acta Pathol Jpn. 1992 Jul;42(7):529-35 [1384272.001]
  • [Cites] Am J Clin Pathol. 1991 Jan;95(1):51-4 [1670974.001]
  • (PMID = 15310407.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC514615
  •  go-up   go-down


3. Kim ST, Lee J, Lee KT, Lee JK, Lee KH, Choi SH, Heo JS, Choi DW, Park SH, Park JO, Lim HY, Park YS, Kang WK: The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. Med Oncol; 2010 Dec;27(4):1149-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
  • Adenocarcinoma arising from the ampulla of Vater is a rare neoplasm that accounts for only 0.2% of all gastrointestinal tract malignancies and has limited data regarding its frontline therapy.
  • We investigated the treatment outcomes in patients with advanced adenocarcinoma of the ampulla of Vater receiving frontline cisplatin-based combination chemotherapy.
  • We analyzed 29 patients with advanced adenocarcinoma of the ampulla of Vater who had been treated by frontline cisplatin-based combination chemotherapy between June 2003 and April 2008.
  • The median time to progression (TTP) was 4.9 months (95% CI, 3.4-6.4), and the median overall survival (OS) was 12.5 months (95% CI, 10.6-14.4).
  • There were no grade 3 or 4 nonhematologic toxicities or treatment-related deaths.
  • The cisplatin-based combination chemotherapy showed moderate activity and a favorable toxicity profile as a frontline treatment for patients with advanced adenocarcinoma of the ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ampulla of Vater / drug effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Common Bile Duct Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 2009 Mar;20(3):191-6 [19396018.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):158-63 [15698732.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2038-45 [18759326.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2598-603 [19164203.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):246-51 [15655540.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] World J Gastroenterol. 2009 Jun 14;15(22):2689-92 [19522017.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):666-73 [19153121.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • (PMID = 19898973.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Ajiki T, Habara K, Kamigaki T, Nakamura T, Fujino Y, Suzuki Y, Takeyama Y, Kuroda Y, Nakamura T: Expression of thymidylate synthase in cancer of the ampulla of Vater. Oncol Rep; 2001 Jul-Aug;8(4):759-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of thymidylate synthase in cancer of the ampulla of Vater.
  • The clinical and therapeutic significance of thymidylate synthase (TS) in cancers of the ampulla of Vater have not yet been reported.
  • We immunohistochemically evaluated TS expression in 33 ampullary cancers using an anti-TS antibody.
  • Although TS expression was not identified as an important factor for postoperative survival, recurrent cases in patients with chemotherapy existed only in the high TS group.
  • In the present study, it was found that TS expression itself in cancers of the ampulla of Vater has no impact in predicting the prognosis of ampullary cancers, but a chemotherapeutic benefit of evaluating TS expression may exist.
  • [MeSH-major] Adenocarcinoma / enzymology. Ampulla of Vater / enzymology. Biomarkers, Tumor / metabolism. Common Bile Duct Neoplasms / enzymology. Thymidylate Synthase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11410778.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


5. Hazama K, Suzuki Y, Takahashi M, Takahashi Y, Yoshioka T, Takano S, Kondoh S, Katoh H: Primary small cell carcinoma of the common bile duct, in which surgical treatment was performed after neoadjuvant chemotherapy: report of a case. Surg Today; 2003;33(11):870-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of the common bile duct, in which surgical treatment was performed after neoadjuvant chemotherapy: report of a case.
  • Most cases occur in the gallbladder or in the ampulla of Vater, and such cases in the common bile duct (CBD) are extremely rare.
  • In this case, neoadjuvant chemotherapy followed by pylorus-preserving pancreaticoduodenectomy showed an excellent response.
  • To our knowledge, this is the first reported case of small cell carcinoma of the CBD in which a radical resection was performed after successful neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Biopsy, Needle. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14605962.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Cascón Fonseca LF, Guerrero Gallego J, Balongo de la Vega A: [Three cases of villous adenoma of the Vater papilla]. Gastroenterol Hepatol; 2000 Apr;23(4):174-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of villous adenoma of the Vater papilla].
  • [Transliterated title] Tres casos de adenoma velloso de papila de Vater.
  • A series of three cases of villous adenoma of the papilla of Vater is reported.
  • In two cases, the pathological diagnosis made before, during and after surgery was of benign villous adenoma.
  • In the third case, the diagnosis made before and during surgery was of adenoma but in the postsurgical examination a macro-invading carcinoma was found.
  • Total resection, rather than a duodenopancreatectomy, was performed due to the length of time from detection of the recurrence until the second operation as well as to the small size of the recurrent tumor in the surgical examination.
  • [MeSH-major] Adenoma, Villous / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10863858.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


7. Bogoevski D, Chayeb H, Cataldegirmen G, Schurr PG, Kaifi JT, Mann O, Yekebas EF, Izbicki JR: Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy. J Gastrointest Surg; 2008 Nov;12(11):1830-7; discussion 1837-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.
  • BACKGROUND: To assess the prognostic significance of nodal microinvolvement in patients with carcinoma of the papilla of Vater.
  • The vast majority of patients were operated upon pancreatic ductal adenocarcinoma (n = 566, 73%), followed by carcinomas of the papilla of Vater (n = 112, 14%), pancreatic neuroendocrine carcinomas (n = 39, 5%), intraductal papillary mucinous neoplasms (n = 33, 4%), and distal bile duct carcinomas (n = 27, 3%).
  • Fresh-frozen tissue sections from 169 lymph nodes (LNs) classified as tumor free by routine histopathology from 57 patients with R0 resected carcinoma of the papilla of Vater who had been spared from adjuvant chemotherapy were immunohistochemically (IHC) examined, using a sensitive IHC assay with the anti-epithelial monoclonal antibody Ber-EP4 for tumor cell detection.
  • RESULTS: Of the 169 "tumor-free" LNs, 91 LNs (53.8%) contained Ber-EP4-positive tumor cells.
  • CONCLUSIONS: The influence of occult tumor cell dissemination in LNs of patients with histologically proven carcinoma of the papilla of Vater supports the need for further tumor staging through immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1989 Jan;21(1):11-5 [2474791.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Scand J Gastroenterol. 1999 Aug;34(8):808-12 [10499482.001]
  • [Cites] Eur J Surg Oncol. 1987 Oct;13(5):409-11 [3311817.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] Lifetime Data Anal. 1995;1(2):195-204 [9385101.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:42-9 [8368769.001]
  • [Cites] HPB (Oxford). 2007;9(2):135-9 [18333129.001]
  • [Cites] Eur J Surg. 1996 Dec;162(12):961-7 [9001878.001]
  • [Cites] J Clin Pathol. 1981 Jul;34(7):779-84 [7021603.001]
  • [Cites] Immunol Today. 1997 Feb;18(2):89-95 [9057360.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46 [10421536.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):928-33 [12845952.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):410-4 [1617591.001]
  • [Cites] Chirurg. 2000 Feb;71(2):196-201 [10734589.001]
  • [Cites] Ann Chir. 2006 May;131(5):322-7 [16615931.001]
  • [Cites] Ann Surg. 1983 Sep;198(3):386-97 [6615059.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Surgery. 2001 May;129(5):537-46 [11331445.001]
  • [Cites] Pathologe. 2003 May;24(3):196-203 [12739053.001]
  • [Cites] World J Gastroenterol. 2006 Oct 28;12(40):6515-21 [17072983.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1827-32 [8083707.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):993-1000; discussion 1000-1 [15570205.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6836-40 [11156375.001]
  • [Cites] J Clin Pathol. 1990 Mar;43(3):213-9 [1692040.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1027-31 [7679945.001]
  • [Cites] Br J Cancer. 1986 Oct;54(4):631-6 [3535864.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):664-8 [4053908.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):493-8 [7680382.001]
  • [Cites] World J Surg Oncol. 2006 Mar 08;4:14 [16524478.001]
  • [Cites] Am J Surg. 1996 Nov;172(5):463-8; discussion 468-9 [8942545.001]
  • [Cites] Ann Thorac Surg. 1994 Nov;58(5):1569-70 [7979715.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Feb;23(2):137-47 [2450753.001]
  • [Cites] Z Gastroenterol. 1998 May;36(5):479-81 [9654711.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Lancet. 1990 Jun 30;335(8705):1565-8 [1972494.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):523-7 [1520589.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • (PMID = 18791769.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW: Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):436-41
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • PURPOSE: To evaluate the role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • METHODS AND MATERIALS: Between January 1991 and December 2002, 118 patients with ampulla of Vater cancer underwent en bloc resection.
  • Postoperative radiotherapy was delivered to the tumor bed and regional lymph nodes, for a total dose of up to 40 Gy delivered in 2-Gy fractions, with a planned 2-week rest period halfway through the treatment period.
  • When age, type of operation, T stage, N stage, histologic differentiation, and the use of adjuvant chemoradiotherapy were incorporated into the Cox proportional hazard model, there was an improvement in the locoregional relapse-free survival rate (p = 0.0050) and a trend toward a longer overall survival (p = 0.0762) associated with the use of adjuvant chemoradiotherapy.
  • CONCLUSIONS: Adjuvant chemoradiotherapy may enhance locoregional control and overall survival in patients with ampulla of Vater cancer after curative resection, especially in those with nodal involvement.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Irradiation. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394162.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW: Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys; 2008 Mar 1;70(3):735-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
  • PURPOSE: The role of adjuvant chemoradiation therapy (CRT) in the treatment of ampullary cancers remains undefined.
  • We retrospectively compared treatment outcomes in patients treated with pancreaticoduodenectomy alone versus those who received additional adjuvant CRT.
  • METHODS AND MATERIALS: Between May 1990 and January 2006, 54 of 96 patients with ampullary adenocarcinoma who underwent potentially curative pancreaticoduodenectomy also received adjuvant CRT.
  • The median preoperative radiation dose was 45 Gy (range, 30-50.4 Gy) and median postoperative dose was 50.4 Gy (range, 45-55.8 Gy).
  • Concurrent chemotherapy included primarily 5-fluorouracil (52%) and capecitabine (43%).
  • On univariate analysis, age, gender, race/ethnicity, tumor grade, use of adjuvant treatment, and sequencing of adjuvant therapy were not significantly associated with LC, DC, or OS.
  • However, on univariate analysis, T3/T4 tumor stage was prognostic for poorer LC and OS (p = 0.02 and p < 0.001, respectively); node-positive disease was prognostic for poorer LC (p = 0.03).
  • On multivariate analysis, T3/T4 tumor stage was independently prognostic for decreased OS (p = 0.002).
  • CONCLUSIONS: Ampullary cancers have a distinctly better treatment outcome than pancreatic adenocarcinomas.
  • Higher primary tumor stage (T3/T4), an independent adverse risk factor for poorer treatment outcomes, may warrant the addition of adjuvant CRT to pancreaticoduodenectomy.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980502.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Wu TC, Shao YF, Shan Y, Wu JX, Zhao DB, Xu LB, Zhao P: [Prognostic implication of common bile duct infiltration in adenocarcinoma of the ampulla of Vater after pancreaticoduodenectomy]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):775-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic implication of common bile duct infiltration in adenocarcinoma of the ampulla of Vater after pancreaticoduodenectomy].
  • OBJECTIVE: To investigate the prognostic implication of common bile duct infiltration in the adenocarcinoma of the ampulla of Vater after panreaticoduodenectomy.
  • METHODS: A retrospective study was conducted on clinical manifestation, pathological behavior and survival data in 102 patients with Vater's ampulla adenocarcinoma, who underwent pancreaticoduodenectomy from Jan 1980 to Dec 2003.
  • CONCLUSION: If the adenocarcinoma of the Vater's ampulla infiltrated the common bile duct, the invasion to the pancreatic medulla is likely developed, and usually with a poor non-recurrence and overall survival.
  • Therefore, postoperative chemotherapy/radiotherapy is suggested.
  • [MeSH-major] Adenocarcinoma. Ampulla of Vater. Common Bile Duct / pathology. Common Bile Duct Neoplasms. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173811.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Sawaki A, Mizuno N, Hoki N, Ishikawa H, Takagi T, Yamao K: [Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2301-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater].
  • We report a case of recurrent carcinoma of the ampulla of Vater with multiple lung and abdominal lymph node metastases that well responded to S-1, an oral fluoropyrimidine.
  • A 56-years-old woman underwent a pylorus-preserving pancreaticoduodenectomy for carcinoma of the ampulla of Vater in October 2003.
  • Computed tomography showed multiple abdominal lymph node metastases.
  • The patient was treated with S-1 (80 mg/day, day 1-28, followed by 2 weeks rest) from November 2003.
  • Anti-tumor efficacy was confirmed to be partial response by Response Evaluation Criteria in Solid Tumors (RECIST).
  • S-1 might be an effective and safe agent for carcinoma of the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Antimetabolites, Antineoplastic / therapeutic use. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / surgery. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079635.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


12. Pamukcuoglu M, Oksuzoglu B, Abali H, Akoglu M, Atalay F, Budakoglu B, Uncu D, Ozdemir NY, Guler T, Zengin N: Prognostic factors and clinicopathological characteristics of carcinoma of ampulla Vateri. Int Surg; 2008 Jul-Aug;93(4):214-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and clinicopathological characteristics of carcinoma of ampulla Vateri.
  • The aim of this study was to describe the clinicopathological characteristics and prognostic factors of carcinoma of ampulla Vateri.
  • The performance status at the time of admission of (European Cooperative Oncology Group) 18 patients (56.3%) were ECOG-1; 8 patients (25.0%) were ECOG-2.
  • Fourteen patients received adjuvant treatment.
  • Ten out of 14 patients were treated with chemotherapy.
  • ECOG performance status (P = 0.06), stage (P = 0.05), perineural invasion (P = 0.01), tumor grade (P = 0.01), and treatment with chemotherapy, chemoradiotherapy, or only radiotherapy (P = 0.001) had a statistically significant impact on overall survival, whereas only tumor histopathology (P < 0.001) was shown to have a statistically significant effect on disease-free survival.
  • Carcinoma of ampulla Vateri is a rare gastrointestinal tumor.
  • Prospective trials with larger number of patients are needed to determine the prognostic factors to help select patients for adjuvant treatment.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19731856.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T: A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol; 2009 Dec;65(1):113-20
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy.
  • METHODS: Patients with histologically or cytologically confirmed, measurable biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer, who were not suitable candidates for surgery, were eligible for the study.
  • The median progression-free survival was 1.6 months, and the overall median survival time was 6.5 months.
  • In the 85 patients who received this UFD chemotherapy in previous and late phase II studies, multivariate analysis revealed the ECOG performance status 1 (P = 0.001), gallbladder as the primary cancer site (P = 0.014), T-factor 4 of the TNM classification (P = 0.035), and elevated serum lactate dehydrogenase levels (P = 0.043) as being associated with a significantly shorter survival.
  • CONCLUSIONS: Combination chemotherapy of UFT and doxorubicin had minimum activity against advanced biliary tract cancer.
  • Performance status was identified as the most important prognostic factor in patients who received systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Biliary Tract Neoplasms / drug therapy. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Ampulla of Vater / pathology. Bile Ducts, Intrahepatic / pathology. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / mortality. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Rate. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404641.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


14. Keene KS, Rich TA, Penberthy DR, Shepard RC, Adams R, Jones RS: Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys; 2005 May 1;62(1):97-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronomodulated delivery of chemotherapy was chosen on the basis of a lower toxicity profile in the treatment of GI malignancies.
  • The median radiation dose was 50.4 Gy given in 28 fractions.
  • Concurrent chemotherapy with 5-FU was administered 5 d/wk, with a median total dose of 8.4 g/m2 (300 mg/m2/d).
  • Toxicities were recorded using the Radiation Therapy Oncology Group grading system.
  • If the 3 patients with carcinoma of the ampulla were removed from the data set, the mean overall survival in the resected patients was 34 months, with a 3-year and 5-year actuarial survival rate of 40% and 17%, respectively.
  • Seven resected patients, four of whom had no evidence of disease, developed diabetes mellitus 1-2 years after radiotherapy.
  • Additional study is warranted to evaluate chronomodulated radiosensitizing chemotherapy schedules in prospective trials and with attention to late effects after radiotherapy, including diabetes mellitus.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / administration & dosage. Chronotherapy. Fluorouracil / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850908.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Witzigmann H, Loracher C, Geissler F, Wagner T, Tannapfel A, Uhlmann D, Caca K, Hauss J, Hehl JA: Neuroendocrine tumours of the duodenum. Clinical aspects, pathomorphology and therapy. Langenbecks Arch Surg; 2002 Jan;386(7):525-33
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumours of the duodenum. Clinical aspects, pathomorphology and therapy.
  • They represent a heterogeneous spectrum of subtypes and may be associated with von Recklinghausen's disease type I (VRD) and multiple endocrine neoplasia type I.
  • There are few studies concerning the biological characteristics and adequate therapy of these tumours.
  • PATIENTS AND METHODS: We report on a retrospective analysis of 12 patients with NTs of the duodenum: six non-ampullary (naNTs) and six ampullary tumours (aNTs).
  • Clinical and histopathological features, therapy and follow-up were evaluated retrospectively and compared with the literature.
  • Of the six patients with naNTs, four were treated by local excision (two endoscopically, two surgical resection), one by Kausch-Whipple operation and in one patient the tumour was an incidental finding in the Billroth II specimen.
  • Four of the six patients with aNTs underwent Kausch-Whipple procedure, one patient ampullectomy (gangliocytic paraganglioma) and one patient palliative chemotherapy.
  • Tumour size of aNTs had no correlation with depth of invasion and metastases.
  • Immunohistochemically tumour cells expressed somatostatin in 5 of 6 aNTs and gastrin in 1 of 6 aNTs and in two gastrinomas.
  • Two patients died for reasons not related to the tumour.
  • Tumour excision of both patients with gastrinomas was not curative.
  • One patient with palliative treatment of a metastasising aNT is alive 66 months after diagnosis.
  • CONCLUSION: Non-ampullary duodenal NTs differ clinically, histologically and immunohistochemically as well as with respect to the extent of resection from NTs of the ampulla of Vater.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11819111.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Harder J, Blum HE: [Cholangiocarcinoma]. Praxis (Bern 1994); 2002 Aug 21;91(34):1352-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are a heterogeneous group of neoplasias that include the most common perihilar or Klatskin tumor (60%), the intrahepatic (peripheral) CCC, the extrahepatic bile duct cancer, the gallbladder cancer and the cancer of the ampulla of Vater.
  • At the time of diagnosis only 20% of patients can be treated by surgery, that offers the only chance for cure.
  • Neither chemotherapy nor radiation therapy improves survival.
  • In patients not eligible for curative surgery prevention or treatment of cholestatis is the main objective.
  • Palliative chemotherapy results in response rates up to 20%.
  • By combining different treatment modalities significant survival can be achieved in some patients.
  • Evidence Based Medicine studies are needed before treatment strategies can be recommended for clinical practice.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis
  • [MeSH-minor] Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / pathology. Hepatic Duct, Common / pathology. Humans. Klatskin Tumor / diagnosis. Klatskin Tumor / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12233266.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 24
  •  go-up   go-down


17. Wiedmann M, Schoppmeyer K, Witzigmann H, Hauss J, Mössner J, Caca K: [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder]. Z Gastroenterol; 2005 Mar;43(3):305-15
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder].
  • [Transliterated title] Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen.
  • Biliary neoplasms are classified into intra- and extrahepatic cholangiocarcinoma (Klatskin tumour, middle and distal extrahepatic tumours), gallbladder cancer, and ampullary carcinoma.
  • Transformation of normal into malignant bile duct tissue requires a chain of consecutive gene mutations, similar to the adenoma-dysplasia-carcinoma-sequence in colon cancer.
  • Abdominal ultrasound, combined non-invasive magnetic resonance cholangiography/tomography (MRC/MRT), and facultatively endoscopic retrograde cholangiography (ERC) for unclear diagnosis, represent the gold standard for primary diagnosis.
  • For ampullary carcinoma, endosonography and endoscopic biopsy are the diagnostic tools of choice.
  • In contrast, there has been no clinical benefit for adjuvant and neoadjuvant therapies.
  • For palliation, bile duct stenting and photodynamic therapy are established methods.
  • Radio- and chemotherapy should be reserved for clinical studies.
  • New therapeutic approaches include brachytherapy, the use of modern chemotherapeutics, COX-2- and tyrosine kinase-receptor-inhibitors.
  • [MeSH-minor] Algorithms. Ampulla of Vater. Bile Ducts / pathology. Bile Ducts, Intrahepatic. Biopsy. Brachytherapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / therapy. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / therapy. Cyclooxygenase Inhibitors / therapeutic use. Gallbladder / pathology. Hepatectomy. Hepatic Duct, Common. Humans. Klatskin Tumor / diagnosis. Klatskin Tumor / therapy. Magnetic Resonance Imaging. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Factors. Stents. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Z Gastroenterol. 2005 May;43(5):473-5 [15871071.001]
  • (PMID = 15765304.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors
  • [Number-of-references] 153
  •  go-up   go-down


18. Ammori BJ: Laparoscopic hand-assisted pancreaticoduodenectomy: initial UK experience. Surg Endosc; 2004 Apr;18(4):717-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 62-year-old man who presented with painless obstructive jaundice was found at endoscopy, to have an ampullary tumor.
  • Preoperative biopsy specimens confirmed the diagnosis of an adenocarcinoma, and CT showed no evidence of either vascular involvement or metastatic disease.
  • The operative time was 11 h (plus a 30-min break).
  • Histology demonstrated an ampullary adenocarcinoma with clear resection margins and involvement of two of the 13 lymph nodes examined.
  • At 2-month follow-up, the patient remains well and is receiving adjuvant chemotherapy.
  • The early promising results with this approach will undoubtedly encourage wider adoption of this procedure and are likely to widen the selection criteria.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Laparoscopy / methods. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Blood Transfusion. Chemotherapy, Adjuvant. Combined Modality Therapy. England. Follow-Up Studies. Hand. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2002 May;16(5):781-4 [11997821.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Chir Ital. 2001 May-Jun;53(3):279-89 [11452812.001]
  • [Cites] Acta Chir Belg. 2003 Apr;103(2):203-7 [12768864.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):918-20 [12632136.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):17-22 [12577229.001]
  • [Cites] Am Surg. 2003 Jul;69(7):578-80 [12889620.001]
  • [Cites] Surg Endosc. 1999 Feb;13(2):157-60 [9918620.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 1999 Aug;6(3):289-95 [10459029.001]
  • [Cites] Semin Laparosc Surg. 2001 Jun;8(2):114-25 [11441400.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Jun;11(3):155-60 [11444743.001]
  • [Cites] Int J Surg Investig. 2000;2(1):41-7 [12774337.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):1-7 [11753036.001]
  • [Cites] Surg Endosc. 1994 May;8(5):408-10 [7915434.001]
  • [Cites] Transplantation. 2002 Jul 27;74(2):169-72 [12151727.001]
  • [Cites] Semin Laparosc Surg. 1996 Mar;3(1):15-20 [10401098.001]
  • [Cites] Surg Endosc. 1994 Nov;8(11):1272-84 [7831596.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1057-65 [12016486.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):854-9 [10896382.001]
  • (PMID = 15214369.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Santini D, Perrone G, Vincenzi B, Lai R, Cass C, Alloni R, Rabitti C, Antinori A, Vecchio F, Morini S, Magistrelli P, Coppola R, Mackey JR, Tonini G: Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol; 2008 Apr;19(4):724-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer.
  • BACKGROUND: Gemcitabine is an acceptable alternative to best supportive care in the treatment of advanced biliary tract cancers.
  • Moreover, recent reports indicate a significant correlation between immunohistochemical variations of hENT1 in tumor samples and survival after gemcitabine therapy in patients with solid tumors.
  • MATERIALS AND METHODS: We used immunohistochemistry to assess the abundance and distribution of hENT1 in tumor samples from radically resected cancer of the ampulla, and sought correlations between immunohistochemical results and clinical parameters including disease outcomes.
  • No statistical significant differences were found between immunohistochemical findings and patient characteristics (sex, age, and tumor-node-metastasis).
  • CONCLUSIONS: hENT1 expression is a molecular prognostic marker for patients with resected ampullary cancer and holds promise as a predictive factor to assist in chemotherapy decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187485.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Equilibrative Nucleoside Transporter 1; 0 / Ki-67 Antigen; 0 / SLC29A1 protein, human
  •  go-up   go-down


20. Snady H: Interventional endoscopy, neoadjuvant therapy and the gastroenterologist. Hematol Oncol Clin North Am; 2002 Feb;16(1):53-79
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.
  • With current treatment, survival of greater than 1 year should be anticipated for many patients with pancreatic cancer.
  • Relief of biliary obstruction allows improvement in liver function and more time to evaluate tumor stage accurately to determine initial treatment (see Fig. 1).
  • A cost-effective algorithm to determine accurate stage and treatment can start with the size of the mass on initial imaging studies.
  • EUS-guided FNA represents a significant improvement over CT scan-guided FNA to make a tissue diagnosis.
  • Tumors reliably staged as unresectable by nonoperative imaging methods including EUS are treated with chemotherapy with or without concurrent radiotherapy because median survival of these patients is 2 years in some series.
  • Rather than reliance on any single standard, clinical judgment and communication among the team are paramount to providing optimal care for patients with a pancreatic neoplasm.
  • [MeSH-major] Adenocarcinoma / therapy. Endoscopy. Endoscopy, Gastrointestinal. Endosonography. Neoadjuvant Therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Ampulla of Vater / surgery. Antineoplastic Agents / therapeutic use. Autonomic Nerve Block / methods. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Chemotherapy, Adjuvant. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Cholestasis / therapy. Combined Modality Therapy. Common Bile Duct Neoplasms / surgery. Diagnostic Imaging / methods. Gastric Outlet Obstruction / surgery. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Staging / methods. Pain Management. Palliative Care. Pancreatic Cyst / therapy. Prognosis. Radiotherapy, Adjuvant. Stents

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063829.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 115
  •  go-up   go-down


21. Schwarz RE, Smith DD, Keny H, Iklé DN, Shibata SI, Chu DZ, Pezner RD: Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysis. Am J Clin Oncol; 2003 Feb;26(1):16-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For periampullary cancer,intraoperative radiation therapy (IORT) administered to the site with the highest locoregional recurrence risk carries the rationale to improve tumor control.
  • IORT impact on postoperative outcomes after pancreatectomy for adenocarcinoma was analyzed, with a specific attempt to correct for the nonrandom IORT treatment assignment, and to account for treatment group imbalances in the interpretation of outcome differences.
  • A propensity-score-adjusted analysis, based on variable selection by logistic regression, was used to rebalance treatments.
  • Diagnoses included pancreatic (n = 36), duodenal (n = 11), ampullary (n = 10), and bile duct cancer (n = 4).
  • Thirty patients received IORT to the resection area, with a median dose of 15 Gy (range: 10-20), followed by postoperative external beam radiation (n = 24).
  • IORT had no significant impact on hospital stay (overall median: 17 days), disease-free survival (16 months), and overall survival (23 months) when adjusted for those most relevant variables reflecting IORT treatment group assignment propensity.
  • We continue to explore IORT in combination with systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Ampulla of Vater. Bile Duct Neoplasms / radiotherapy. Duodenal Neoplasms / radiotherapy. Pancreatic Neoplasms / radiotherapy. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Period. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12576918.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, Kalykaki A, Milaki G, Georgoulias V, Androulakis N: A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. Oncology; 2010;78(5-6):356-60
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.
  • PURPOSE: To evaluate the efficacy and tolerability of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) as first-line treatment of advanced biliary tract cancer.
  • The median overall survival time was 9.2 months (95% CI 5.8-12.5) and the median progression-free survival time 2.7 months (95% CI 2.2-3.2).
  • There were no treatment-related deaths.
  • CONCLUSION: The combination of oxaliplatin and irinotecan has a modest antitumor activity with manageable toxicity as first-line treatment in metastatic cancer of the biliary tract and therefore it cannot be recommended as front-line treatment for unresectable biliary tract cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Biliary Tract Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Ampulla of Vater / pathology. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / pathology. Female. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright ©2010 S. Karger AG, Basel.
  • (PMID = 20798557.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


23. Nabeshima S, Kishihara Y, Nabeshima A, Yamaga S, Kinjo M, Kashiwagi S, Hayashi J: Poorly differentiated adenocarcinoma with signet-ring cells of the Vater's ampulla, without jaundice but with disseminated carcinomatosis. Fukuoka Igaku Zasshi; 2003 Jul;94(7):235-40
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated adenocarcinoma with signet-ring cells of the Vater's ampulla, without jaundice but with disseminated carcinomatosis.
  • To reduce tumor cells in number and improve DIC, 11 cycles of 5-Fluorouracil and leucovorin therapy were done, and the patient survived for 12 months.
  • Autopsy showed a 0.8 cm diameter, poorly differentiated adenocarcinoma with the signet-ring cell type in the lamina propria of the Vater's ampulla.
  • Many metastatic foci and micro tumor emboli were found in the lung and in bone marrow.
  • These findings suggest that the origin of the cancer may have been located in the Vater's ampulla.
  • This is a rare case of an ampullary tumor of poorly differentiated adenocarcinoma with the signet-ring cell type, without jaundice but with multiple metastasis.
  • 5-Fluorouracil and leucovorin were effective for increasing survival time and improving quality of life.
  • [MeSH-major] Ampulla of Vater. Bone Marrow Neoplasms / secondary. Carcinoma, Signet Ring Cell / pathology. Common Bile Duct Neoplasms / pathology. Lung Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disseminated Intravascular Coagulation / complications. Disseminated Intravascular Coagulation / drug therapy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Jaundice. Leucovorin / administration & dosage. Male. Middle Aged. Neoplastic Cells, Circulating / pathology. Quality of Life

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14509231.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Sikora SS, Balachandran P, Dimri K, Rastogi N, Kumar A, Saxena R, Kapoor VK: Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol; 2005 Mar;31(2):158-63
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemo-radiotherapy in ampullary cancers.
  • PURPOSE: Patterns of failure following surgical treatment of ampullary cancers indicate that up to 45% of patients develop loco-regional recurrence.
  • PATIENTS AND METHODS: From January 1989 to December 2000, 113 patients underwent pancreatico-duodenectomy for ampullary cancer.
  • Forty-nine patients received adjuvant chemo-radiotherapy (median dose 50.4 Gy with concurrent 5-Flurouracil) and long-term outcome in these patients was compared with those 55 who did not receive adjuvant therapy.
  • No significant difference in median survival (34.6 vs 24.5 months; P=0.3) and actuarial 5-year survival rates (38 vs 28%) was seen between those who received and those who did not receive adjuvant therapy.
  • CONCLUSIONS: Adjuvant chemo-radiotherapy did not improve the long-term survival or decrease recurrence rates in patients with ampullary cancers who had undergone pancreatico-duodenectomy.
  • [MeSH-major] Ampulla of Vater / drug effects. Ampulla of Vater / radiation effects. Common Bile Duct Neoplasms / therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant / adverse effects. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Incidence. India / epidemiology. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Pancreaticoduodenectomy. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698732.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement